INTRODUCTION
Bowel obstruction is often the terminal complication of advanced abdominal cancer, and can persist for several weeks or months until the patient dies. 1 The obstruction gives rise to a vicious cycle of increased intestinal secretions and fluid accumulation, distension, and peristaltic activity, with the resultant damage to the intestinal epithelium eliciting an inflammatory response. 2 The symptoms, principally continuous abdominal pain, colic, nausea, and vomiting, generally have a slow onset. Once established, however, symptoms are severe.
Most cases of bowel obstruction due to advanced cancer are managed medically because of the questionable value of surgery in resolving symptoms, particularly in light of high morbidity and/or mortality risks. 3 Management is likely to require intravenous hydration and parenteral nutrition alongside pharmaceutical interventions. The latter will often include corticosteroids, which may resolve the obstruction, although the underlying mechanism is unclear, 4 and antiemetics, antisecretory drugs, and analgesics as symptomatic treatments. 2 A temporary nasogastric tube (NGT) may be needed to drain stomach contents and reduce vomiting while pharmaceutical interventions are started or as a long-term measure if drug therapy has not controlled symptoms. NGTs, however, are particularly distressing for patients and preclude hospital discharge; NGT removal is thus a key goal.
Somatostatin analogs (SSAs) are among the antisecretory drugs recommended in inoperable bowel obstruction. 2 SSAs inhibit the release of various gastrointestinal hormones, thus reducing gastrointestinal secretions and slowing intestinal motility, decreasing splanchnic blood flow, and increasing water and electrolyte absorption. 5, 6 The pharmacokinetic profile of the microparticle formulation of the SSA lanreotide is well suited to the symptomatic treatment of inoperable bowel obstruction in palliative care. Following a single 30-mg intramuscular injection, there is an initial lanreotide release from microparticle surfaces, followed by prolonged release (approximately 2 weeks) associated with the subsequent enzymatic breakdown of copolymer microparticles. 7 The aim of this study was to investigate the efficacy and safety of 30 mg of lanreotide microparticles as a symptomatic treatment for inoperable bowel obstruction due to peritoneal carcinomatosis. In light of the paucity of high-quality data to support health care interventions in palliative care generally, and in the use of SSAs in inoperable bowel obstruction specifically, a randomized controlled trial (RCT) was conducted.
PATIENTS AND METHODS

Patients
Adults (older than 18 years of age) with peritoneal carcinomatosis (confirmed by computed tomography within the previous 3 months) were eligible if they had a digestive obstruction (stomach, duodenum, or small bowel) of malignant origin and were experiencing two or more vomiting episodes per day or had an NGT, and if surgery was inappropriate (documented in medical records or confirmed by surgical advice within the previous 72 hours). Patients were included if they had been treated with intravenous corticosteroids for Ն 5 days and intravenous proton pump inhibitors and had an estimated survival time of more than 1 month. Patients were excluded if there were signs of bowel perforation; if they had been receiving anti-H 2 receptor blockers, any anticancer therapy within the previous 15 days, somatostatin, or any SSA for the bowel obstruction; if they had a contraindication to intramuscular injections; or if they had participated in another clinical study within the previous 30 days. Patients provided written informed consent before completing studyrelated procedures.
Trial Design and Interventions
The study was conducted in 22 hospitals across Belgium, France, and the Netherlands between September 24, 2003, and September 15, 2008. The trial was approved by local independent ethics committees and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Key changes to trial conduct are noted in Appendix Table A1 (online  only) . The study is registered with ClinicalTrials.gov (NCT00216372).
The first part of the study was a 10-day, randomized, double-blind, placebo-controlled investigation of 30 mg of lanreotide microparticles (Beaufour-Ipsen Industrie, Dreux, France), as a symptomatic treatment. Patients were randomly assigned to treatment according to two computergenerated randomization lists created and held confidentially by the sponsor; one list was for the presence and one for the absence of an NGT, and each had a fixed block size of four (two lanreotide, two placebo). The sponsor placed the visually indistinguishable treatments in numbered containers and dispatched them in randomization blocks to study sites. Treatment numbers comprised a two-digit number (01 or 02) for the NGT stratum and a four-digit sequence number. Investigators enrolled patients and allocated them in turn to the smallest treatment number for the relevant stratum. Investigators then administered a single intramuscular lanreotide or placebo injection on day 1.
Patients completing either treatment arm of the double-blind phase continued into the open-label phase at the investigators' and patients' discretion and received one injection of 30 mg of lanreotide microparticles every 10 days until they decided to stop treatment or died. This report focuses on data from the double-blind phase; safety data for the open-label phase are provided in Appendix Table A2 (online only) .
Concomitant treatments were standardized at baseline to ensure comparability of treatment groups: (1) intravenous corticosteroids: Ն 1 mg/kg per day methylprednisolone (or equivalent for other corticosteroids) for Ն 5 days previously with no dose adjustment during that time, (2) intravenous proton pump inhibitors: 40 mg per day omeprazole (or equivalent) for Ն 3 days previously with no dose adjustment during that time, and (3) antispasmodics or antiemetics: used for Ն 3 days previously with no dose adjustment during that time. Analgesic use was unrestricted. Modifications to concomitant treatments other than analgesics were not permitted during the first 7 days. Prohibited treatments comprised antisecretories other than proton pump inhibitors, SSAs (except lanreotide microparticles), and cyclosporine.
Patients without a baseline NGT were withdrawn if an NGT was inserted during the first 7 days. In addition, patients could leave the study at any time by withdrawing consent or following the investigator's decision.
Assessments and End Points
Visits were scheduled at days 0, 3, 7, 10 (double-blind phase), and 20 (openlabelphase),withthetimingofafinalvisitdeterminedbytreatmentterminationor patient death. Patients recorded symptoms on diary cards by using a visual analog scale (VAS) to rate well-being and severity of abdominal pain every day during both study phases. A clinical examination was performed at all visits; information on adverse events (AEs) was collected at all visits except day 0.
The primary efficacy end point was the proportion of patients responding to treatment at day 7. A responder was defined as a patient with one or fewer vomiting episodes per day or who had no recurrence of vomiting after NGT removal (for Ն 3 consecutive days during days 1 through 7 in both cases). Any patient who died before day 7 was considered a nonresponder. The proportion of responders was primarily assessed from diary card information. Investigators' assessment of responders was a supportive analysis (see Statistical Analyses).
Secondary efficacy end points comprised changes from baseline in vomiting frequency (patients without baseline NGT) or secretion volumes (patients with baseline NGT), number of nausea episodes, abdominal pain intensity, well-being, number of days without vomiting, time to onset of symptom improvement (defined as time elapsed between study drug injection and first day of clinical response before day 7), and duration of symptom relief (number of 3-day periods in which there was a treatment response). Safety variables included treatment-emergent AEs (TEAEs), vital signs, and biochemical measures.
Statistical Analyses
The planned sample size of 40 patients per group was based on having 80% power to detect a difference between treatment groups in the proportion of responders by using a two-sided test with a 5% significance level and assuming 20% and 55% response rates in placebo and lanreotide groups, respectively, with 10% of patients having nonevaluable data. The primary efficacy analysis for the primary end point was the proportion of responders, determined from patients' diary cards for the intent-totreat (ITT) population (ie, all randomly assigned patients receiving at least one assigned treatment injection). Supportive analyses were performed by using investigators' subjective assessments of responders at day 7 for the ITT population and for diary card data for the per protocol (PP) population (ie, randomly assigned patients receiving at least one assigned treatment injection and following the protocol without major deviation). Between-group differences were analyzed by using a logistic regression model that included treatment group and stratum as independent variables; the treatment-by-stratum interaction was not significant at the 10% level and was removed from the final model. Missing data were not imputed.
The ITT population was used for secondary efficacy end point analyses. Analyses of covariance (ANCOVAs) with treatment group as the main factor and baseline value as covariate were performed for most of these end points (changes in number of vomiting episodes, secretion volumes, episodes of nausea [additional main factor: stratum], and abdominal pain and well-being [repeated measures ANCOVA with day, stratum, treatment-by-day, and treatment-by-stratum as additional factors]). For the number of days without vomiting episodes, a negative binomial regression was performed (independent variables: treatment group and stratum; offset variable: number of evaluated days between days 1 and 7). For the time to onset of symptom improvement, median and quartiles (95% CIs) were determined by using the Kaplan-Meier method. All statistical tests were two-sided with a 5% significance level. Descriptive statistics were used for the duration of response and safety variables. Safety variables were assessed for the safety population (ie, all patients receiving at least one assigned treatment injection). Statistical analyses were performed with SAS software (version 9.1).
RESULTS
Patient Disposition and Baseline Characteristics
Eighty patients were randomly assigned (lanreotide, n ϭ 43; placebo, n ϭ 37) and 67 (84%) completed the double-blind phase (lanreotide, n ϭ 35; placebo, n ϭ 32; Fig 1) . Fifty-nine patients entered the open-label lanreotide phase (lanreotide, n ϭ 31; placebo, n ϭ 28); patients originally randomly assigned to lanreotide received a median of one injection and those originally randomly assigned to placebo received a median of two injections during the open-label phase.
The ITT population for the double-blind phase comprised all 80 randomly assigned patients, and the PP population comprised 49 patients (lanreotide, n ϭ 26; placebo, n ϭ 23). The most common reasons for exclusion from the PP population were modification of concomitant treatments (except analgesics) during the first 7 days (lanreotide, n ϭ 8; placebo, n ϭ 6) and/or not satisfying one or more inclusion criteria (lanreotide, n ϭ 6; placebo, n ϭ 3; Appendix Table  A3 , online only).
Baseline demographic characteristics were similar between treatment groups (Table 1 ). In terms of disease characteristics, the primary cancer location was most commonly genital (51.3% [n ϭ 41]) or digestive (33.8% [n ϭ 27]); the whole group was severely impaired (Eastern Cooperative Oncology Group [ECOG] grade 3 or 4; 63.8% [lsqb]n ϭ 51]), although, clinically, impairment was more severe in the lanreotide than in the placebo group; most patients (82.5% [n ϭ 66]) were fed by a parenteral-only route. A total of 51 (63.8%) of 80 patients had a baseline NGT.
Efficacy End Points
Primary end point. More patients receiving lanreotide than placebo were responders (Fig 2) . However, the difference between groups was not statistically significant for the primary analysis (ITT) on the Change from baseline in visual analog scale (VAS) score for patient well-being during the double-blind phase. VAS range: 0 mm ("I don't feel well at all") to 100 mm ("I feel very well"). Data are adjusted mean and SE from diary cards for the intent-to-treat population. Using prespecified analyses, differences between groups were significant for days 3 (difference 8.8 mm; 95% CI, 0.4 to 17.2 mm; P ϭ .04), 6 (difference 10.4 mm; 95% CI, 0.6 to 20.2 mm; P ϭ .04), and 7 (difference 13.2 mm; 95% CI, 3.3 to 23.1 mm; P ϭ .01), but the treatment difference between overall means was not significant (P ϭ .07). A post hoc linear contrast, however, revealed a significant overall difference between the slopes for the two treatment groups (P ϭ .01). SD, standard deviation. and 7 (Fig 3) . In a post hoc linear contrast test, however, overall between-group differences were significant (P ϭ .01).
Differences between treatment groups for other efficacy end points were not significant ( Table 2 ). The intensity of abdominal pain generally remained low during double-blind treatment (Appendix Fig A1) . The first quartile and median times to symptom improvement were 2.0 days (95% CI, 1.0 to 4.0 days) and 5.0 days (95% CI, 3.0 to Ͼ 7 days) with lanreotide (n ϭ 24), respectively; for placebo, they were 2.0 days (95% CI, 1.0 to 3.0 days) and 4.0 days (95% CI, 2.0 to Ͼ 7 days; n ϭ 21; Appendix Fig A2) .
Safety End Points
Many patients experienced TEAEs in the double-blind phase (lanreotide, 72.1% [n ϭ 31]; placebo, 67.6% [n ϭ 25]; (Table 3) Table A3 (online only).
DISCUSSION
The double-blind RCT is the mainstay methodologic tool for evaluating health care interventions. The paucity of such trials in palliative care, however, reflects significant methodologic challenges in this setting, not the least of which are difficulties with recruitment, controlling for numerous comorbidities, and the ethics of denying treatments. It is perhaps not surprising that goodquality data supporting the use of SSAs in inoperable intestinal obstruction due to advanced cancer are currently limited. To the best of our knowledge, this is the first RCT conducted with lanreotide in such patients. Two key findings emerge. First, significantly more patients receiving 30 mg of lanreotide microparticles than placebo responded to treatment in terms of reduced vomiting for two of the three analyses conducted. Second, improvements in patient well-being were significantly better with lanreotide than with placebo. These well-being improvements were apparent without significant changes in secretion volumes among patients with NGTs or in nausea and vomiting among patients without NGTs. This suggests that the discomfort and indignity of uncontrolled nausea and vomiting (with or without NGTs) are sufficiently profound that even modest symptom reduction leads to considerably improved patient well-being. In terms of safety, lanreotide was well tolerated. Only three TEAEs were considered related to study drug; for lanreotide, these were moderate dry mouth and mild diabetes.
The reduction of vomiting and well-being improvements are key goals in this patient population. NGT insertion is quite distressing, particularly because bowel obstructions may persist for weeks or even months. NGT removal also potentially facilitates hospital discharge. In this study, significantly more patients responded in terms of reduced vomiting with lanreotide than with placebo in the PP diary card analysis. Although this was not the primary population for the responder analysis defined by the study protocol, the clinical relevance of the population should not be overlooked. As is to be expected in palliative care, many patients deviated from the protocol, principally by failing to satisfy inclusion criteria and by using concomitant medications. This introduced confounding factors into the ITT diary card analysis and may explain the lack of a statistically significant difference between treatments. It is also important to note that the difference between treatment groups for the PP analysis was significant despite disease severity being greater in the lanreotide than in the placebo group. In addition, significance was achieved despite fewer patients with an NGT being considered treatment responders compared with those without an NGT, suggesting the treatment-response criteria in the former may have been disproportionately stringent.
Although there are no previous RCTs with an SSA in this specific population (ie, obstruction due to peritoneal carcinomatosis), data from this RCT resonate with those from uncontrolled studies in malignant bowel obstruction showing symptom improvements with octreotide. Several studies have shown that octreotide can reduce NGT secretions and support NGT removal, and it can also reduce nausea severity and vomiting frequency in patients without NGTs. 1, [10] [11] [12] In the only published RCT directly comparing symptom relief from octreotide and hyoscine butylbromide in inoperable malignant bowel obstruction, octreotide reduced gastrointestinal secretions significantly more effectively than hyoscine butylbromide at days 2 and 3 of treatment. 12 NGT removal was possible-with or without adjustment of antisecretory medication-in 13 (76.5%) of 17 patients, with octreotide showing a trend toward greater efficacy. Importantly, adequate parenteral hydration helped reduce nausea and drowsiness, independent of antisecretory agents. Although all these studies were in small numbers of patients, their relevance and clinical applicability support the findings from our study. Moreover, a qualitative systematic review of randomized trials that investigated medical treatment in inoperable bowel obstruction due to advanced cancers concluded that octreotide was more effective in relieving symptoms than hyoscine butylbromide. 13 The strength of this study lies in efforts to ensure that comparisons between lanreotide and placebo were rigorous. In particular, inclusion criteria were strict. For example, patients were included only if they were receiving stable corticosteroid doses, agents known to alleviate intestinal obstructions. 4 Tight restrictions were also adopted for concomitant treatments. These factors probably exacerbated recruitment difficulties, which necessitated an extended recruitment period, and contributed to incomplete randomization blocks and, accordingly, slight imbalances in patients' functional well-being at baseline between treatment groups. They probably also limited the PP population size (several exclusions were due to violations of restrictions on concomitant treatment). Two further limitations of the study should be mentioned. First, we acknowledge that disease progression has limited value as a safety end point as a result of its inevitability in this population but have nonetheless included the data because it was a predetermined secondary end point. Second, subgroup analyses of patients with and without NGTs were based on small patient numbers, so the conclusions that can be drawn are limited. These limitations notwithstanding, the rigorous approach to the study underpins our confidence in its findings and their clinical relevance.
This study shows that it is feasible to overcome many of the methodologic challenges inherent in conducting RCTs in this setting and should spur further study. It is important to note that trial participants benefit from clinical research, particularly from enhanced medical care. We suggest, on the basis of our findings, that future SSA trials might use a clinically meaningful composite end point involving measures of both vomiting frequency and well-being.
Additional research in the challenging circumstances of palliative care is welcome. However, on the basis of this RCT, the body of evidence in similar fragile patient populations, and the lack of effective therapeutic options, lanreotide is a feasible second-line symptomatic treatment option after corticosteroids for inoperable bowel obstruction due to peritoneal carcinomatosis. 8 implemented in SAS PROC FREQ using the network algorithm of Mehta and Patel. 9 A serious adverse event was an adverse event resulting in death or that was life threatening, resulting in prolonged hospitalization, causing persistent or significant disability or birth defect, or requiring medical or surgical intervention to prevent one of the other outcomes.
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